23andme - Search News

23andMe weighing up sale of company

newsbytesapp.com · 9h

23andMe considers sale amid financial struggles and leadership turmoil

By the 2023 fiscal year, 23andMe had reported a net loss of $312 million and its individual share price has plummeted a staggering 98% since going public.

BioPharma Dive · 1h

23andMe considers a sale as cash runs low

The testing company ended last year with $79 million and told investors it will need to raise money to fund its operations and financial commitments.

Hosted on MSN · 19h

23andMe weighing up sale of the company as cash runs dry

Me is considering a sale of the company as it weighs up strategic options, capping a torrid year for the genetic testing business. A special committee of its directors’ board is considering various directions for the company in addition to a sale,

ENDPOINTS NEWS · 1d

23andMe weighs a sale as cash dwindles

Embattled genetics testing giant 23andMe is thinking of selling itself as it runs out of cash. The company needs to raise more money to continue …

13don MSN

23andMe has been quietly exploring a possible sale of its telehealth business, Lemonaid

The struggling genetic-testing 23andMe is looking for a buyer for the virtual-care business it acquired in 2021, Business ...

1d

23andMe is exploring strategic alternatives, looking to raise capital

23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter ...

1d

Genetic test maker 23andMe eyes strategic alternatives, including a sale

Genetic testing pioneer 23andMe is looking at strategic alternatives, including a possible sale, it said Tuesday, months ...

1d

23andMe Board Explores Strategic Alternatives Amid Restructuring

23andMe Holding Co. ( ME, Financials) announced that its board's Special Committee is reviewing strategic alternatives, ...

What went wrong at 23andMe? Why the genetic-data giant risks collapse

At-home DNA testing is no longer in high demand — and critics have raised concerns about unreliable tests and privacy.

1d

23andMe Reports Third Quarter Fiscal Year 2025 Financial Results

Company Notes Continued Concerns Regarding Liquidity and Consideration of Potential Ways to Address Operational and Financial ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results